Belgium-based biopharmaceutical company TiGenix has reported positive topline week 104 results from the Phase III clinical trial (ADMIRE-CD) of Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease.

Cx601 is an investigational suspension of allogeneic, expanded adipose-derived stem cells (eASC) developed for Crohn's disease patients with inadequate response to at least one conventional or biologic therapy, including antibiotics, immunosuppressants or anti-TNF agents.

The randomised, double-blind, placebo-controlled Phase III trial evaluated the efficacy and safety of a single administration of Cx601 in 212 patients.

TiGenix chief medical officer Marie Paule Richard said: "The week 104 data on the patients who stayed in the trial continue to prove the value of Cx601 for this very difficult-to-treat patient population, and are consistent with the results communicated at week 24 and week 52.

"The randomised, double-blind, placebo-controlled Phase III trial evaluated the efficacy and safety of a single administration of Cx601 in 212 patients."

"Not only did this long-term extension show the safety and tolerability of Cx601 but it indicates that clinical remission was maintained after a single administration of Cx601, compared with best available standard of care two years after administration."

During the extension from week 52 to week 104, which was performed to confirm the long-term safety and tolerability, it was found that 23 patients in the Cx601 arm concluded the extension when compared to 14 in the placebo arm.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The tolerability and safety profiles were also found to be consistent with the results observed at week 24 and week 52.

Cx601 secured orphan designation from the European Commision in 2009 for the treatment of anal fistulas.